Alaunos Therapeutics, Inc. (TCRT) stock forecast & analysis
3.03
NasdaqCM · USDDelayed by 15 minutes
Up: +1.98, +188.6%
1 analysis
Latest analysis: · verdict locked
- Open
- 1.74
- Previous close
- 1.05
- Day range
- 1.51 – 4.32
- 52-week range
- 0.7200 – 4.50
- Volume (shares)
- 247.39M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 2.93M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- -0.87
- Market cap
- 8.87M
Market Scanner’s AI analysis of Alaunos Therapeutics, Inc. (TCRT), updated October 2026: Alaunos Therapeutics' acquisition of Velaris Therapeutics and strong technical indicators dominated recent analyses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Alaunos Therapeutics, Inc. (TCRT) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Alaunos Therapeutics' acquisition of Velaris Therapeutics and strong technical indicators dominated recent analyses.
Recent analyses for TCRT covered a significant acquisition of Velaris Therapeutics, which coincided with a notable surge in the company's share price. The market analyst report detailed exceptionally strong technical indicators, including substantial price appreciation and robust momentum across various timeframes. The fundamentals analyst report provided an overview of the company's financial performance, noting declining revenues and significant net losses.
TCRT news & sentiment
News reports highlighted significant corporate activity, including an acquisition that led to a share price surge and broader market interest. Social media discussions were not covered in the provided notes.
TCRT technical picture
The company's stock exhibited significant price appreciation, with its current price substantially above both the 50-day and 200-day simple moving averages, indicating a strong uptrend. Momentum indicators, including RSI and MFI, showed exceptionally strong readings, suggesting sustained and high volume-weighted buying pressure, while the MACD neared a bullish crossover.
Fundamentals
The company reported declining revenues over the past few fiscal years, with negative gross profit and significant net losses. The trailing twelve months showed a negative return on equity, indicating substantial profitability challenges.
Factors discussed — upside
- Strong technical indicators including significant price appreciation and robust momentum.
- Aggressive recent rally with substantial 7-day and 30-day price changes.
- Acquisition of Velaris Therapeutics announced and completed, leading to a share price surge.
Factors discussed — risks
- Declining annual revenue over fiscal years 2024 and 2025.
- Negative gross profit and significant net losses reported.
- Low market capitalization of $8.87 million as of June 30, 2026.
- Technical indicators
- Corporate acquisition
- Financial performance
- Biotechnology sector activity
Summary updated .
TCRT technical indicators
Common technical indicators for TCRT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.51 | Price above |
| 10-day exponential moving average | 1.30 | Price above |
| Relative strength index (14-day) | 81.21 | Overbought |
| MACD line (12/26/9) | -0.0129 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.16 – 2.10 | Price above the upper band |
Analyses
Recent TCRT.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-14 TCRT.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Alaunos Therapeutics, Inc.?
- The bull case for TCRT is supported by strong technical indicators, including significant price appreciation and robust momentum, alongside an aggressive recent rally. The recent acquisition of Velaris Therapeutics also contributed to a share price surge, as noted in the analyses.
- What are the risks for Alaunos Therapeutics, Inc.?
- Risks for TCRT include declining annual revenues and significant net losses, with negative gross profit reported. The company also has a low market capitalization, which was noted in the fundamentals analysis.
- Is Alaunos Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of Alaunos Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for TCRT is supported by strong technical indicators, including significant price appreciation and robust momentum, alongside an aggressive recent rally. The recent acquisition of Velaris Therapeutics also contributed to a share price surge, as noted in the analyses. Discussed risks: Risks for TCRT include declining annual revenues and significant net losses, with negative gross profit reported. The company also has a low market capitalization, which was noted in the fundamentals analysis. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Alaunos Therapeutics, Inc.?
- News reports highlighted significant corporate activity, including an acquisition that led to a share price surge and broader market interest. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Alaunos Therapeutics, Inc.?
- Every analysis of Alaunos Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Alaunos Therapeutics, Inc.?
The bull case for TCRT is supported by strong technical indicators, including significant price appreciation and robust momentum, alongside an aggressive recent rally. The recent acquisition of Velaris Therapeutics also contributed to a share price surge, as noted in the analyses.
What are the risks for Alaunos Therapeutics, Inc.?
Risks for TCRT include declining annual revenues and significant net losses, with negative gross profit reported. The company also has a low market capitalization, which was noted in the fundamentals analysis.
Is Alaunos Therapeutics, Inc. bullish or bearish?
Recent AI analyses of Alaunos Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for TCRT is supported by strong technical indicators, including significant price appreciation and robust momentum, alongside an aggressive recent rally. The recent acquisition of Velaris Therapeutics also contributed to a share price surge, as noted in the analyses. Discussed risks: Risks for TCRT include declining annual revenues and significant net losses, with negative gross profit reported. The company also has a low market capitalization, which was noted in the fundamentals analysis. These are descriptive observations, not a recommendation.
What is the latest sentiment on Alaunos Therapeutics, Inc.?
News reports highlighted significant corporate activity, including an acquisition that led to a share price surge and broader market interest. Social media discussions were not covered in the provided notes.
How does Market Scanner analyse Alaunos Therapeutics, Inc.?
Every analysis of Alaunos Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh TCRT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.